Une médecine individualisée change l’horizon des pharmas
S’il est trop tôt pour parler de la fin des médicaments à un milliard de dollars annuel (blockbusters), leur nombre sera fort...
Manuela Palma De Figueiredo
- ABB LTD N44.87-0.4%
- ALCON N80.220.83%
- RICHEMONT N145.450.45%
- GEBERIT N587.80.34%
- GIVAUDAN N40140.38%
- HOLCIM N94.981.02%
- KUEHNE+NAGEL INT N178.05-3.13%
- LOGITECH N67.062.16%
- LONZA N590.23.33%
- NESTLE N87.560.57%
- NOVARTIS N90.94-0.19%
- PARTNERS GROUP N1112.51.27%
- ROCHE GS258-0.73%
- SIKA N207.60.63%
- SONOVA HOLDING AG253.50%
- SWISS LIFE HOLDING AG N841.20.17%
- SWISS RE N149.950.54%
- SWISSCOM N540.50.09%
- UBS GROUP N26.031.01%
- ZURICH INSURANCE N577.4-0.96%
- ABB LTD N44.87-0.4%
- ALCON N80.220.83%
- RICHEMONT N145.450.45%
- GEBERIT N587.80.34%
- GIVAUDAN N40140.38%
- HOLCIM N94.981.02%
- KUEHNE+NAGEL INT N178.05-3.13%
- LOGITECH N67.062.16%
- LONZA N590.23.33%
- NESTLE N87.560.57%
- NOVARTIS N90.94-0.19%
- PARTNERS GROUP N1112.51.27%
- ROCHE GS258-0.73%
- SIKA N207.60.63%
- SONOVA HOLDING AG253.50%
- SWISS LIFE HOLDING AG N841.20.17%
- SWISS RE N149.950.54%
- SWISSCOM N540.50.09%
- UBS GROUP N26.031.01%
- ZURICH INSURANCE N577.4-0.96%